Biotech Active Stocks: Pfizer Inc. (NYSE:PFE), Geron Corporation (NASDAQ:GERN), Cell Therapeutics (NASDAQ:CTIC), Chelsea Therapeutics International (NASDAQ:CHTP)

A US federal court yesterday invalidated Pfizer Inc.’s (NYSE:PFE) key patent covering its anti-inflammatory pill Celebrex. The patent, which was set to lapse in December 2015, would have given Pfizer an 18-month extension from the expiry of the patent for the major ingredient in the drug, celecoxib. Pfizer Inc. (NYSE:PFE) stock performance was -2.69% in last session and finished the day at $31.12. Traded volume … Continue reading Biotech Active Stocks: Pfizer Inc. (NYSE:PFE), Geron Corporation (NASDAQ:GERN), Cell Therapeutics (NASDAQ:CTIC), Chelsea Therapeutics International (NASDAQ:CHTP)

Investor’s Alert: Plug Power Inc (NASDAQ:PLUG), SIRIUS XM Holding (NASDAQ:SIRI), General Electric Company (NYSE:GE), Pfizer Inc. (NYSE:PFE)

Shares of Plug Power Inc (NASDAQ:PLUG) rose Thursday after the company narrowed a quarterly per-share loss and said it expected to break even this year and quadruple orders. Plug Power Inc (NASDAQ:PLUG) stock performance was 17.65% in last session and finished the day at $8.00. Traded volume was 130,939,920 million shares in the last session and the average volume of the stock remained 37.58 million … Continue reading Investor’s Alert: Plug Power Inc (NASDAQ:PLUG), SIRIUS XM Holding (NASDAQ:SIRI), General Electric Company (NYSE:GE), Pfizer Inc. (NYSE:PFE)

Geron Corporation (NASDAQ:GERN) got bad news about its key imetelstat drug, as the FDA issued a clinical hold on the treatment for multiple myeloma and essential thrombocythemia. Geron Corporation (NASDAQ:GERN) stock performance was -61.59% in last session and finished the day at $1.69. Traded volume was 46,444,384 million shares in the last session and the average volume of the stock remained 4.64 million shares. The … Continue reading Biotech Most Active Stocks: Geron Corporation (NASDAQ:GERN), Pfizer Inc. (NYSE:PFE), OXiGENE Inc (NASDAQ:OXGN), Gilead Sciences (NASDAQ:GILD)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Net loss for the fourth quarter ended December 31, 2013 was $74.2 million, or $0.40 per share, compared to a net loss of $60.5 million, or $0.36 per share, for the same period in 2012. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock … Continue reading Biotech Active Runners: Ariad Pharmaceuticals (NASDAQ:ARIA), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Novavax (NASDAQ:NVAX)

Pfizer Inc. (NYSE:PFE) has begun testing an over-the-counter version of Lipitor, the blockbuster drug that has plumped up the pharmaceutical giant’s coffers for more than a decade. Pfizer Inc. (NYSE:PFE) stock performance was 2.22% in last session and finished the day at $32.69. Traded volume was 26,325,091 million shares in the last session and the average volume of the stock remained 26.27 million shares. The … Continue reading Healthcare Sector Most Active: Pfizer Inc. (NYSE:PFE), Novavax (NASDAQ:NVAX), Boston Scientific Corporation (NYSE:BSX), Dendreon Corporation (NASDAQ:DNDN)

PTC Inc. (NASDAQ:PTC) on Wednesday reported fiscal first-quarter profit of $30.3 million. On a per-share basis, the Needham, Massachusetts-based company said it had net income of 26 cents. Earnings, adjusted for one-time gains and costs, were 50 cents per share. PTC Inc. (NASDAQ:PTC) belongs to Technology sector. Its net profit margin is 11.80% and weekly performance is -2.77%. On last trading day company shares ended … Continue reading Notable Ups And Down: PTC Inc. (NASDAQ:PTC), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Symetra Financial Corporation (NYSE:SYA), Sonic Corp. (NASDAQ:SONC)